Article Figures & Data
Figures
- Figure 1.
Tofacitinib: Phase 3 Studies of 1 to 2 Year Duration—ORAL Sync, Standard, and Scan
DMARD=disease-modifying antirheumatic drug; IR=nonresponder; MTX=methotrexate.
Reproduced with permission from IB McInnes, PhD.
Tables
Tools
Development, Safety, and Efficacy of Janus Kinase Inhibitors in Rheumatoid Arthritis
Permalink:
